If you looked solely at its stock price, you might get the idea that Eli Lilly (NYSE: LLY) is having a bit of an off quarter.

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem ...

Healthcare giant Eli Lilly (NYSE: LLY) has been trading at an inflated valuation for some time thanks to excitement around ...

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...

Indianapolis-based pharmaceutical giant Eli Lilly and Company has purchased 30.9 acres of vacant land to the north and to the ...

We recently compiled a list of the 10 Best S&P 500 Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Eli Lilly (LLY) has been one of the most searched ... While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to ...

Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Eli Lilly's quarterly sales and earnings underperformed, a rare stumble for the company and its weight loss drug ...